Nadim Mitra K, Dua Renee, Campese Vito M
Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, 1200 N. State Street, Los Angeles, CA 90033, USA.
Curr Cardiol Rep. 2004 Nov;6(6):403-8. doi: 10.1007/s11886-004-0046-3.
In the United States, 50 million Americans are estimated to have hypertension. Over the past several decades, it has become clear that hypertension is both a cause and a consequence of kidney disease. In contrast to the striking decline in mortality rates from both stroke and coronary heart disease, the prevalence of hypertension as a cause of end-stage renal disease (ESRD) has increased such that it is now the second most common cause of ESRD in the United States. Hypertension and proteinuria occur in most patients with chronic kidney disease and are risk factors for faster progression of kidney disease. Antihypertensive agents reduce blood pressure and urine protein excretion and slow the progression of kidney disease. The level of blood pressure achieved and use of renin-angiotensin-aldosterone system-blocking agents is critical for delaying progression of renal disease in all ethnic groups.
据估计,美国有5000万美国人患有高血压。在过去几十年中,很明显高血压既是肾脏疾病的一个病因,也是其一个后果。与中风和冠心病死亡率显著下降形成对比的是,作为终末期肾病(ESRD)病因的高血压患病率有所上升,以至于它现在是美国ESRD的第二大常见病因。大多数慢性肾病患者会出现高血压和蛋白尿,它们是肾病进展加快的危险因素。抗高血压药物可降低血压、减少尿蛋白排泄并减缓肾病进展。在所有种族群体中,所达到的血压水平以及使用肾素 - 血管紧张素 - 醛固酮系统阻断剂对于延缓肾病进展至关重要。